Kenvue Inc.
KVUEAPI behind this page
KVUE Q2 2025 request
Playground key active
/api/financials?ticker=KVUE&year=2025&quarter=2
Pick an endpoint and run the request.Income Statement
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Revenue | 3,839 | 4,000 | -4.0% |
Show Business Segments breakouts |
|||
| Essential Health | 1,225 | 1,262 | -2.9% |
| Self Care | 1,555 | 1,635 | -4.9% |
| Skin Health and Beauty | 1,059 | 1,103 | -4.0% |
| Cost of Revenue | 1,578 | 1,635 | -3.5% |
Show Counterparty Name breakouts |
|||
| Johnson & Johnson | 38 | 47 | -19.1% |
Show Restructuring Plan breakouts |
|||
| 2024 Multi-Year Restructuring Initiative | 6 | 9 | -33.3% |
| Gross Profit | 2,261 | 2,365 | -4.4% |
| Selling, General & Administrative | 1,504 | 1,641 | -8.3% |
Show Counterparty Name breakouts |
|||
| Johnson & Johnson | 2 | 59 | -96.6% |
Show Restructuring Plan breakouts |
|||
| 2024 Multi-Year Restructuring Initiative | 2 | 1 | +100.0% |
| Restructuring Charges | 60 | 48 | +25.0% |
Show Restructuring Plan breakouts |
|||
| 2024 Multi-Year Restructuring Initiative | 60 | 48 | +25.0% |
| Other Operating Income Expense Net | 5 | 12 | -58.3% |
| Operating Income | 692 | 154 | +349.4% |
| Non-Operating Income (Expense) | 10 | -3 | +433.3% |
| Interest Income Expense Nonoperating Net | 94 | 92 | +2.2% |
| Income Before Taxes | 588 | 65 | +804.6% |
| Income Tax Expense (Benefit) | 168 | 7 | +2300.0% |
| Net Income | 420 | 58 | +624.1% |
Show Equity Components breakouts |
|||
| Retained Earnings | 420 | 58 | +624.1% |
Show Related Party Transaction breakouts |
|||
| Net Economic Benefit Arrangements · Parent | 14 | 19 | -26.3% |
| EPS (Basic) | 0.22 | 0.03 | +633.3% |
| EPS (Diluted) | 0.22 | 0.03 | +633.3% |
| Wtd Avg Shares (Basic) | 1,919 | 1,915 | +0.2% |
| Wtd Avg Shares (Diluted) | 1,928 | 1,920 | +0.4% |
| Research & Development | 91 | 105 | -13.3% |
| Other Non-Operating Income (Expense) | -1 | -3 | +66.7% |
| Comprehensive Income | 1,047 | -102 | +1126.5% |
| Other Comprehensive Income | 627 | -160 | +491.9% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -5 | 3 | -266.7% |
| Accumulated Other Comprehensive Income | 627 | -160 | +491.9% |
| Accumulated Translation Adjustment | 613 | -152 | +503.3% |
| Gain on Derivatives and Hedges | 19 | -11 | +272.7% |
Balance Sheet
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 1,070 | — | — |
| Accounts Receivable | 2,331 | 2,240 | +4.1% |
| Inventory | 1,776 | 1,849 | -3.9% |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Primary Beneficiary | 27 | 26 | +3.8% |
| Prepaid Expenses & Other Current Assets | 525 | 557 | -5.7% |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Primary Beneficiary | 13 | 2 | +550.0% |
Show Counterparty Name breakouts |
|||
| Johnson & Johnson | 100 | 151 | -33.8% |
| Other Assets Current | 152 | 221 | -31.2% |
| Total Current Assets | 5,854 | 5,881 | -0.5% |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Primary Beneficiary | 242 | 207 | +16.9% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 2,038 | 2,004 | +1.7% |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Primary Beneficiary | 4 | 2 | +100.0% |
| Goodwill | 9,486 | 8,973 | +5.7% |
Show Business Segments breakouts |
|||
| Essential Health | 1,679 | 1,624 | +3.4% |
| Self Care | 5,482 | 5,161 | +6.2% |
| Skin Health and Beauty | 2,325 | 2,188 | +6.3% |
| Deferred Tax Assets | 220 | — | — |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Primary Beneficiary | 2 | — | — |
| Other Non-Current Assets | 730 | — | — |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Primary Beneficiary | 5 | — | — |
Show Counterparty Name breakouts |
|||
| Johnson & Johnson | 90 | — | — |
| Total Assets | 27,132 | 26,443 | +2.6% |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Primary Beneficiary | 253 | 212 | +19.3% |
| Intangible Assets | 3,929 | 3,841 | +2.3% |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Customer Relationships | 884 | 901 | -1.9% |
| Other Intangible Assets | 588 | 612 | -3.9% |
| Patents and trademarks | 2,457 | 2,328 | +5.5% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 8,804 | 8,762 | +0.5% |
Show Indefinite Lived Intangible Assets By Major Class breakouts |
|||
| Other Intangible Assets | 61 | 55 | +10.9% |
| Trademarks | 4,814 | 4,866 | -1.1% |
| Current Liabilities | |||
| Debt Current | 1,553 | 1,427 | +8.8% |
| Accounts Payable | 2,568 | — | — |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Primary Beneficiary | 3 | — | — |
Show Related Party Transaction breakouts |
|||
| Net Economic Benefit Arrangements · Parent | 28 | — | — |
| Accrued Liabilities | 1,081 | 1,262 | -14.3% |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Primary Beneficiary | 13 | 11 | +18.2% |
| Accrued Rebates Returns And Promotions Current | 697 | 715 | -2.5% |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Primary Beneficiary | 17 | 13 | +30.8% |
| Accrued Income Taxes Current | 89 | — | — |
| Total Current Liabilities | 5,988 | 5,937 | +0.9% |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Primary Beneficiary | 33 | 27 | +22.2% |
| Commercial Paper | 800 | 670 | +19.4% |
| Current Portion of Long-Term Debt | -749 | -750 | +0.1% |
| Non-Current Liabilities | |||
| Deferred Tax Liabilities | 2,380 | 2,392 | -0.5% |
| Employee Related Liabilities Current And Noncurrent | 371 | 350 | +6.0% |
| Other Non-Current Liabilities | 606 | — | — |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Primary Beneficiary | 3 | — | — |
Show Counterparty Name breakouts |
|||
| Johnson & Johnson | 157 | — | — |
| Total Liabilities | 16,402 | — | — |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Primary Beneficiary | 36 | — | — |
| Operating Lease Liabilities | 96 | — | — |
| Accrued Income Taxes Noncurrent | 208 | 173 | +20.2% |
| Other Liabilities | |||
| Long Term Debt And Lease Obligation Excluding Current Maturities | 7,057 | 7,051 | +0.1% |
| Stockholders' Equity | |||
| Common Stock | 19 | 19 | 0.0% |
| Additional Paid-In Capital | 16,288 | 16,075 | +1.3% |
| Treasury Stock Common Value | -369 | -98 | -276.5% |
| Retained Earnings | -136 | 17 | -900.0% |
| Accumulated Other Comprehensive Income | -5,072 | -5,835 | +13.1% |
| Total Stockholders' Equity | 10,730 | 10,178 | +5.4% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -138 | -161 | +14.3% |
| Accumulated Other Comprehensive Income | -5,072 | -5,835 | +13.1% |
| Accumulated Translation Adjustment | -4,975 | -5,689 | +12.6% |
| Additional Paid In Capital | 16,288 | 16,075 | +1.3% |
| Common Stock | 19 | 19 | 0.0% |
| Gain on Derivatives and Hedges | 41 | 15 | +173.3% |
| Retained Earnings | -136 | 17 | -900.0% |
| Treasury Stock Common | -369 | -98 | -276.5% |
| Total Liabilities & Equity | 27,132 | 26,443 | +2.6% |
Cash Flow Statement
| Metric | YTD Q2 2025 | YTD Q2 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 278 | 290 | -4.1% |
Show Business Segments breakouts |
|||
| Essential Health | 114 | 108 | +5.6% |
| Self Care | 102 | 85 | +20.0% |
| Skin Health and Beauty | 62 | 97 | -36.1% |
| Stock-Based Compensation | 81 | 142 | -43.0% |
| Deferred Income Taxes | -27 | -205 | +86.8% |
| Other Non-Cash Items | 33 | 19 | +73.7% |
| Change in Accounts Receivable | -51 | -233 | +78.1% |
| Change in Inventory | -117 | -49 | -138.8% |
| Increase Decrease In Other Operating Assets | 112 | 35 | +220.0% |
| Increase Decrease In Accounts Payable And Accrued Liabilities | 109 | -237 | +146.0% |
| Increase Decrease In Employee Related Liabilities | -4 | 7 | -157.1% |
| Increase Decrease In Accrued Taxes Payable | -29 | -44 | +34.1% |
| Increase Decrease In Other Operating Liabilities | -78 | 39 | -300.0% |
| Net Cash from Operations | 1,049 | 727 | +44.3% |
| Investing Activities | |||
| Capital Expenditures | -267 | -243 | -9.9% |
| Other Investing Activities | 10 | 6 | +66.7% |
| Net Cash from Investing | -257 | -237 | -8.4% |
| Financing Activities | |||
| Proceeds From Repayments Of Commercial Paper | -25 | 50 | -150.0% |
| Proceeds From Issuance Of Unsecured Debt | 746 | — | — |
| Repayments Of Senior Debt | -750 | — | — |
| Payments Of Dividends | -785 | -766 | -2.5% |
| Share Repurchases | -127 | -91 | -39.6% |
| Proceeds From Payments For Other Financing Activities | 83 | -9 | +1022.2% |
| Net Cash from Financing | -858 | -816 | -5.1% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 66 | -42 | +257.1% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1,070 | 1,014 | +5.5% |
Show Consolidated Entities breakouts |
|||
| Variable Interest Entity Primary Beneficiary | 136 | 122 | +11.5% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.